Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions-Reference-Cited by-同舟云学术

Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions

Published:2018-12 Issue:12 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ba Boubakar¹,Gaudin Karen¹,Désiré Amélie¹,Phoeung Thida¹,Langlois Marie-Hélène¹,Behl Charan R.²,Unowsky Joel²,Patel Indravadan H.²,Malick A. Waseem²,Gomes Melba³,White Nicholas⁴⁵,Kauss Tina¹^ORCID

Affiliation:

1. EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Université Bordeaux, Bordeaux, France

2. Hoffmann-La Roche Inc., Little Falls, New Jersey, USA

3. Consultant, World Health Organization, Geneva, Switzerland

4. Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

5. Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Abstract

Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration.

Funder

Grand Challenges Canada

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01170-18

Reference35 articles.

1. Community-Based Interventions for Improving Perinatal and Neonatal Health Outcomes in Developing Countries: A Review of the Evidence

2. Empiric Treatment of Neonatal Sepsis in Developing Countries

3. Rational development of guidelines for management of neonatal sepsis in developing countries